An interventional pain management practice near Nashville, Tennessee, offering umbilical cord derived regenerative cell injections alongside conventional pain procedures.
This listing and the separate entry under the slug ipc-pain-center both point to the same business, Interventional Pain Center, whose website is ipcpaincenter.com. Directory users should treat the two as one practice. It is an interventional pain management group rather than a dedicated cell therapy clinic, and the regenerative service sits alongside conventional procedures such as diagnostic and therapeutic spinal injections, spinal cord stimulation and prolotherapy.
The cell treatment the site describes is allogeneic (from a donor rather than the patient). It is branded Wharton's jelly regenerative therapy, using cells taken from the Wharton's jelly of umbilical cord tissue. The site states that the tissue comes from live, healthy births after delivery and explicitly states that the cells are not from aborted foetuses, and it says the cord tissue is tested and stored in line with United States Food and Drug Administration compliance requirements. Mesenchymal stem cells are named as the therapeutic cell type; haematopoietic stem cells, which give rise to blood cells, are mentioned in passing rather than as something the clinic injects.
The site carries a clear disclaimer that regenerative therapies of this kind are considered experimental and that none of them are approved by the United States Food and Drug Administration. It also notes that insurance does not generally cover them. This is more transparent than many comparable sites and is worth weighing: it means the treatment is not established care and a patient would be paying privately for something the clinic itself describes as experimental.
The conditions named for the cell treatment are musculoskeletal and spinal: osteoarthritis and degenerative joint disease, knee pain including meniscal and cruciate ligament tears, shoulder pain and rotator cuff injuries, hip pain and chronic lower back pain. The practice lists a team of seven clinicians across two Tennessee sites.
The conditions below are those the site names for its regenerative therapy, alongside the wider spinal and musculoskeletal pain work of the practice.
The site states that its regenerative therapy uses mesenchymal stem cells from the Wharton's jelly of umbilical cord tissue donated after live, healthy births, and that the tissue is tested and stored in line with United States Food and Drug Administration compliance requirements.
The site lists two physicians, two physician assistants and three nurse practitioners.
The practice is an outpatient interventional pain clinic operating from two sites in the Nashville area of Tennessee. The main Nashville office is within Skyline Medical Center at 3443 Dickerson Pike, Suite 730, and there is a second office at 353 New Shackle Island Road, Suite 148C, Hendersonville. Treatment is by injection in a procedure room setting; the site does not describe an on-site cell processing laboratory, which is consistent with the use of a donor-derived product supplied by a third party. No accreditation or language provision is stated.
The site publishes no prices. It does state that insurance coverage is generally not available for the regenerative therapy, which means a patient would expect to pay privately; the amount is not given and would have to be obtained from the clinic.
Profile compiled from information published on the clinic's own website and from the StemCell Registry directory record. Details may change; confirm directly with the clinic before making decisions.